Similar articles

• The federal preemption debate in pharmaceutical labeling product liability actions.

  Gross JM, Curry JA. Gross JM, et al. Tort Trial Insur Pract Law J. 2007 Fall;43(1):35-70. Tort Trial Insur Pract Law J. 2007. PMID: 18354866 No abstract available.
• Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.

  Dorfman HL, Quinn VM, Brophy EA. Dorfman HL, et al. Food Drug Law J. 2006;61(4):585-622. Food Drug Law J. 2006. PMID: 17180765 No abstract available.
• The Supreme Court, preemption, and malpractice liability.

  Kesselheim AS, Studdert DM. Kesselheim AS, et al. N Engl J Med. 2009 Feb 5;360(6):559-61. doi: 10.1056/NEJMp0809403. N Engl J Med. 2009. PMID: 19196672 No abstract available.
• Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.

  Seamon MJ, Clauson KA. Seamon MJ, et al. J Herb Pharmacother. 2005;5(3):67-86. J Herb Pharmacother. 2005. PMID: 16520299 Review.
• Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed.

  Nicholson S, Peterson J, Yektashenas B. Nicholson S, et al. Expert Opin Drug Saf. 2012 Mar;11(2):299-314. doi: 10.1517/14740338.2012.650689. Epub 2012 Jan 10. Expert Opin Drug Saf. 2012. PMID: 22233294 Review.